Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial
International Journal of Radiation Oncology*Biology*Physics · 2023-10 · 117 (2) · 370-377
DOI: 10.1016/j.ijrobp.2023.04.010 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2023-10. Verfasst von Daniel E Spratt und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Cleveland, Ohio. Electronic address: Daniel.Spratt@uhhospitals.org. Hauptthemen laut MEDLINE: Prostatic Neoplasms. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE: Intermediate-risk prostate cancer is a heterogeneous disease state with diverse treatment options. The 22-gene Decipher genomic classifier (GC) retrospectively has shown to improve risk stratification in these patients. We assessed the performance of the GC in men with intermediate-risk disease enrolled in NRG Oncology/RTOG 01-26 with updated follow-up. METHODS AND MATERIALS: After National Cancer Institute approval, biopsy slides were collected from NRG Oncology/RTOG 01-26, a randomized phase 3 trial of men with intermediate-risk prostate cancer randomized to 70.2 Gy versus 79.2 Gy of radiation therapy without androgen deprivation therapy. RNA was extracted from the highest-grade tumor foci to generate the locked 22-gene GC model. The primary endpoint for this ancillary project was disease progression (composite of biochemical failure, local failure, distant metastasis, prostate cancer-specific mortality, and use of salvage therapy). Individual endpoints were also assessed. Fine-Gray or cause-specific Cox multivariable models were constructed adjusting for randomization arm and trial stratification factors. RESULTS: Two-hundred fifteen patient samples passed quality control for analysis. The median follow-up was 12.8 years (range, 2.4-17.7). On multivariable analysis, the 22-gene GC (per 0.1 unit) was independently prognostic for disease progression (subdistribution hazard ratio [sHR], 1.12; 95% confidence interval [CI], 1.00-1.26; P = .04), biochemical failure (sHR, 1.22; 95% CI, 1.10-1.37; P < .001), distant metastasis (sHR, 1.28; 95% CI, 1.06-1.55; P = .01), and prostate cancer-specific mortality (sHR, 1.45; 95% CI, 1.20-1.76; P < .001). Ten-year distant metastasis in GC low-risk patients was 4% compared with 16% for GC high-risk patients. In patients with lower GC scores, the 10-year difference in metastasis-free survival rate between arms was -7%, compared with 21% for higher GC patients (P-interaction = .04). CONCLUSIONS: This study represents the first validation of a biopsy-based gene expression classifier, assessing both its prognostic and predictive value, using data from a randomized phase 3 trial of intermediate-risk prostate cancer. Decipher improves risk stratification and can aid in treatment decision-making in men with intermediate-risk disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Cleveland, Ohio. Electronic address: Daniel.Spratt@uhhospitals.org.
- Veracyte, Inc, South San Francisco, California.
- Department of Radiation Oncology, Washington University, St. Louis, Missouri.
- Princess Margaret Cancer Centre, Cancer Clinical Research Unit, Toronto, Ontario, Canada.
- Department of Pathology, UCSF Medical Center-Mount Zion, San Francisco, California.
- Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Förderung
- NCI NIH HHS
Zitieren
APA
Spratt, D. E., Liu, V. Y. T., Michalski, J., Davicioni, E., Berlin, A., Simko, J. P., Efstathiou, J. A., Tran, P. T., Sandler, H. M., Hall, W. A., Thompson, D. J. S., Parliament, M. B., Dayes, I. S., Correa, R. J. M., Robertson, J. M., Gore, E. M., Doncals, D. E., Vigneault, E., Souhami, L., …, & Feng, F. Y. (2023). Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial. International Journal of Radiation Oncology*Biology*Physics, 117(2), 370-377. https://doi.org/10.1016/j.ijrobp.2023.04.010
Vancouver
Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, et al. Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial. International Journal of Radiation Oncology*Biology*Physics. 2023;117(2):370-377. doi:10.1016/j.ijrobp.2023.04.010
BibTeX
@article{Spratt2023,
author = {Spratt, Daniel E and Liu, Vinnie Y T and Michalski, Jeff and Davicioni, Elai and Berlin, Alejandro and Simko, Jeffry P and Efstathiou, Jason A and Tran, Phuoc T and Sandler, Howard M and Hall, William A and Thompson, Darby J S and Parliament, Matthew B and Dayes, Ian S and Correa, Rohann Jonathan Mark and Robertson, John M and Gore, Elizabeth M and Doncals, Desiree E and Vigneault, Eric and Souhami, Luis and Karrison, Theodore G and Feng, Felix Y},
title = {Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2023},
volume = {117},
number = {2},
pages = {370--377},
doi = {10.1016/j.ijrobp.2023.04.010}
}
EUVIMED